Price
No data yet.
Social Signal Score
Analyst Ratings
18 analystsRevenue
$176.24MAnalyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Christopher Peetz
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 433
- Beta
- 0.49
- Country
- US
- Piotroski score
- 3 / 9 (Weak)
- Altman Z-score
- -0.23
Financials
Revenue
$176.24M+1502.2%Net Income
$-67.23MEBITDA
$-11.37MFree Cash Flow
$-273.70MEPS (diluted)
$-1.06Shares Outstanding (diluted)
63.37M+533.3%Operating Expenses
$172.00MCash & Debt
$438.29MRevenue by Segment (annual)
$521.31MQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $521.31M | $-23.36M | $-0.47 |
| 2024 | $336.89M | $-87.94M | $-1.85 |
| 2023 | $186.37M | $-163.41M | $-4.00 |
| 2022 | $77.06M | $-135.66M | $-4.01 |
| 2021 | $19.14M | $-83.99M | $-2.77 |
| 2020 | $0.00 | $-103.27M | $-4.09 |
| 2019 | $0.00 | $-52.55M | $-2.29 |
| 2018 | $0.00 | $-17.35M | $-0.75 |
Valuation
MIRMhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
100+0.00%Social Signal Score
Mentions (2)
- News (RSS)seekingalpha·3h ago·Neutral
Mirum Pharmaceuticals: The September PDUFA Is The Smallest Catalyst
View source ↗ - Newszacks.com·11d ago·Neutral
Why Is Mirum Pharmaceuticals (MIRM) Up 6.9% Since Last Earnings Report? Mirum Pharmaceuticals (MIRM) reported earnings 30 days ago. What's next for the stock?
View source ↗
Earnings
Tue, Nov 3(in 7 weeks)
Consensus estimate $-0.53 per share
Typical surprise -42.8% (median, so one quarter with a near-zero estimate can't distort it)
- Wed, Aug 5$-1.06 vs $-0.74miss
- Wed, May 6$-13.43 vs $-0.40miss
- Wed, Feb 25$-0.11 vs $0.02miss
- Tue, Nov 4$0.05 vs $-0.10beat
- Wed, Aug 6$-0.12 vs $-0.31beat
- Wed, May 7$-0.30 vs $-0.39beat
Estimates and results for MIRM via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by MIRM officers and directors.
- Bought
- —
- Sold
- $24.8m
0 trades
37 trades
- Howe Jolandasold
- Peetz Christophersold
- Peetz Christophersold
- Howe Jolandasold
- Bjerkholt Ericsold
- Peetz Christophersold
- Peetz Christophersold
- Peetz Christophersold
63 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in MIRM.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.